rilonacept 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
interleukin-1 receptors	5105	501081-76-1

Description:

Molecule

Description

Synonyms:

rilonacept
arcalyst

an anti-arthritis agent derived from IL-1R and IL-1RAcP

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
23	mg	P

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Feb. 27, 2008	FDA	REGENERON PHARMACEUTICALS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Injection site erythema	73.69	44.84	25	363	83149	63405485
Injection site reaction	45.49	44.84	16	372	58508	63430126

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Injection site erythema	94.96	53.54	28	344	78169	79665847
Injection site mass	56.38	53.54	14	358	20170	79723846

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L04AC04	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSUPPRESSANTS IMMUNOSUPPRESSANTS Interleukin inhibitors
MeSH PA	D000893	Anti-Inflammatory Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Cryopyrin associated periodic syndrome	indication	430079001

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Interleukin-1 beta	Cytokine	P01584	IL1B_HUMAN	INHIBITOR	Kd	12.30		DRUG LABEL	DRUG LABEL
Interleukin-1 alpha	Cytokine	P01583	IL1A_HUMAN	INHIBITOR	Kd	11.85		DRUG LABEL
Interleukin-1 receptor antagonist protein	Unclassified	P18510	IL1RA_HUMAN	INHIBITOR	Kd	11.22		DRUG LABEL

External reference:

ID	Source
8K80YB5GMG	UNII
D06635	KEGG_DRUG
4027340	VANDF
C2343589	UMLSCUI
CHEMBL1201830	ChEMBL_ID
DB06372	DRUGBANK_ID
8750	INN_ID
C531377	MESH_SUPPLEMENTAL_RECORD_UI
6790	IUPHAR_LIGAND_ID
763450	RXNORM
136721	MMSL
25332	MMSL
d07138	MMSL
012583	NDDF
430868007	SNOMEDCT_US
434463003	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Arcalyst	HUMAN PRESCRIPTION DRUG LABEL	1	73604-914	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	160 mg	SUBCUTANEOUS	BLA	33 sections
Arcalyst	HUMAN PRESCRIPTION DRUG LABEL	1	73604-914	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	160 mg	SUBCUTANEOUS	BLA	33 sections